ReviewCells2026
Limitations of Stem Cell Therapy for Parkinson's Disease.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Stem cell therapy, as a potential treatment for Parkinson's disease (PD), has been investigated in many clinical trials for its effectiveness. However, the therapeutic outcomes have shown considerable variability. This may be due to certain limitations of stem cell therapies, such as the inability to ameliorate non-motor symptoms or modify underlying disease mechanisms, and the limited applicability in certain patient populations. Combinations with the recently emerging gene therapy and other available technologies are expected to make up for or break down these limitations of stem cell therapy, thereby broadening its scope of application. In this review, we will discuss the limitations of stem cell therapy in terms of pathogenesis, symptoms, and population, as well as possible coping strategies to enhance the effectiveness of stem cell therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.